Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615 1619 1626
This examiner grants 40% of resolved cases
Garen Gotfredson serves as an examiner in Tech Center 1600, Art Unit 1615. With 548 resolved cases, he has a well-established track record that includes an allowance rate of 40.0 percent. This rate suggests a balanced approach to examination, where a significant portion of applications are eventually granted, though many face initial hurdles.
The interview lift of 28.0 percent is a key indicator of Gotfredson’s receptiveness to practitioner input. This substantial lift suggests that interviews are an effective tool for overcoming rejections in Art Unit 1615. Applicants who engage in direct dialogue are statistically much more likely to reach an allowance than those who rely solely on written responses.
The median time to allowance for Gotfredson is 1415 days. This timeline is consistent with the often lengthy prosecution cycles found in Tech Center 1600. Given the 548 resolved cases, the data provides a reliable signal that combining a 40.0 percent allowance rate with a 28.0 percent interview lift can lead to successful outcomes if practitioners are willing to invest the necessary time.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18754995 | THERAPEUTIC AND NON-THERAPEUTIC USES OF A PERSONAL CLEANSING COMPOSITION AND METHODS OF TREATMENT | Non-Final OA | The Procter & Gamble Company |
| 18472478 | HAIR CARE COMPOSITIONS COMPRISING A 2-PYRIDINOL-N-OXIDE MATERIAL AND AN IRON CHELATOR | Final Rejection | The Procter & Gamble Company |
| 17621142 | DEVICE FOR DELIVERING A FLOWABLE TISSUE DRESSING MATERIAL AND METHODS OF USE | Final Rejection | Solventum Intellectual Properties Company |
| 18348787 | DENSIFIED CO-PRECIPITATED MATERIALS ISOLATED BY THIN FILM EVAPORATION | Final Rejection | Merck Sharp & Dohme LLC |
| 18723269 | SYNTHETIC BIOPOLYMERS AND THEIR USE IN COMPOSITIONS FOR TISSUE REPAIR | Non-Final OA | DSM IP ASSETS B.V. |
| 18261523 | PHARMACEUTICAL COMPOSITION | Final Rejection | Novartis AG |
| 18692081 | POWDER COSMETIC | Non-Final OA | SHISEIDO COMPANY, LTD. |
| 17309195 | Deodorant Compositions | Final Rejection | Colgate-Palmolive Company |
| 17620147 | ANTIMICROBIAL PEPTIDE-SELENIUM NANOPARTICLES | Non-Final OA | The University of Melbourne |
| 17772897 | SUN CARE COMPOSITIONS WITH HOLLOW MESOPOROUS SILICA NANOSPHERES | Non-Final OA | ROHM AND HAAS COMPANY |
| 18558827 | SOTORASIB FORMULATION | Final Rejection | AMGEN INC. |
| 17642829 | FLYING PEST CONTROL COMPOSITION AND FLYING PEST CONTROL SPRAY | Non-Final OA | Kao Corporation |
| 18499252 | HIGH TEMPERATURE RESISTANT PROBIOTICS FOR FOOD OR BEVERAGE AND METHOD OF MAKING THE SAME | Final Rejection | Nano and Advanced Materials Institute Limited |
| 18771223 | MULTIFUNCTIONAL (METH)ACRYLATE POLYSACCHARIDE MICROCAPSULES | Non-Final OA | Encapsys, LLC |
| 17611338 | METHODS FOR ENCAPSULATION | Final Rejection | Chr. Hansen A/S |
| 18230227 | USE OF BETA-1,3-GLUCAN FOR MODULATING IMMUNE FUNCTION AND TREATING INTESTINAL INFLAMMATION | Non-Final OA | KEMIN INDUSTRIES, INC. |
| 18011643 | ADJUVANTS | Final Rejection | GLAXOSMITHKLINE BIOLOGICALS SA |
| 17766409 | SOFT CAPSULE | Non-Final OA | SUNSHO PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy